New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

SINGAPORE, April 5, 2024 /PRNewswire/ -- GSK Singapore announced that the Health Sciences Authority (HSA) has approved a new indication and a new strength for Trelegy ...

With a handy lead in COPD, GlaxoSmithKline's Trelegy Ellipta has been positioned well as the leading triple-drug inhaler on the market. But with a major competitor gaining speed, GSK is looking to pad ...

GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...

GlaxoSmithKline and partner Innoviva are seeking an expansion to the US label of their Trelegy Ellipta lung drug. Trelegy Ellipta got its first US approval in September as a daily long-term ...

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market. Top-line results ...

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use ...

The European Medicines Agency has accepted the regulatory submission for expanded use of GlaxoSmithKline’s Trelegy in adult asthma patients. Triple respiratory drug ...

LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...

Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur. Use Trelegy Ellipta with ...